Fig. 3From: Hypothyroidism and hypopituitarism as immune-related adverse events due to lenvatinib plus pembrolizumab therapy in the immediate postoperative period after laparoscopic hepatectomy for liver metastases from gastric cancer: a case reportTransition of Thyroid-stimulating hormone (TSH), Free-T3 and Free-T4 across lenvatinib plus pembrolizumab treatment and operationBack to article page